News
  • EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
  • MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
  • EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
  • HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
ABOUT US
more
ABOUT US

“Client's Success is Our Priority”

EirGenix upholds the mission of providing clients with high-quality and cost-effective CDMO services and biologics. All in order to enhance the wellbeing of individuals and society, and improve the quality of life.

more
Grow together

The most experienced technical team will bring the greatest benefits to customers and patients

The primary task

We hope patients can use affordable high-quality biological drugs

Drug development

Assist customers to go faster and further on the journey of biotechnology drug development, because successfully developed drugs can bring more protection to human health

2012

Eirgenix was established on December 21, 2012

12

12 x 2,000 liter single use bioreactors

1000

Annual production of antibodies can reach up to 1,000kg

Services

EirGenix provides comprehensive cell line development services from DNA replication to the generation of stable producer cell lines for further process development and manufacturing.

more
Products
  • COVID-19 ANTIGEN RAPID TEST

    It can detect COVID-19 and get result in 10 minute!

    More
  • PRODUCT PIPELINE

    Eirgenix develops high quality biologic products, advancing an extensive pipeline of candidates to improve the lives of patients.

    More
  • CRM197 CARRIER PROTEIN
    More